Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 17/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391693 | 1.00 | CCR5 (0.50) | CCR5OPRL1OPRM1OPRK1KMT2A | |
| Hydrochloric Acid SCHEMBL3390783 | 0.99 | CCR5 (0.49) | CCR5OPRL1OPRM1OPRK1KMT2A | |
| Hydrochloric Acid SCHEMBL3390786 | 0.99 | CCR5 (0.49) | CCR5OPRL1OPRM1OPRK1KMT2A | |
| SCHEMBL3387185 | 0.88 | OPRL1 (0.56) | CCR5OPRL1OPRM1OPRK1KMT2A | |
| SCHEMBL3387190 | 0.88 | OPRL1 (0.56) | CCR5OPRL1OPRM1OPRK1KMT2A | |
| Hydrochloric Acid SCHEMBL3391692 | 0.87 | OPRL1 (0.55) | CCR5OPRL1OPRM1OPRK1KMT2A | |
| Hydrochloric Acid SCHEMBL3391698 | 0.87 | OPRL1 (0.55) | CCR5OPRL1OPRM1OPRK1KMT2A | |
| SCHEMBL3387158 | 0.85 | CCR5 (0.54) | CCR5 | |
| SCHEMBL3387164 | 0.85 | CCR5 (0.54) | CCR5 | |
| Hydrochloric Acid SCHEMBL3391810 | 0.85 | CCR5 (0.53) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | claimed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CHAN CHUN KONG LAVAL | 2010-11-11 | — | — | US | disclosed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-7709642-B2 | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286183-A1 | SPIROHYDANTOIN COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | CXCR1, CXCR2, CXCR4 | CCR5 4/4885OPRL1 83/4885OPRM1 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.